Welcome to the e-CCO Library!

P581: Patient-reported complementary and alternative medicine use in IBD: 10 years of observation among patients included in a national cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Pittet1*, N. Aslan2, N. Fournier1, A. Decollogny1, A. Schoepfer2, F. Seibold3, P.-Y. Rodondi4

Created: Thursday, 21 February 2019, 9:14 AM
P581: Pre-operative prolonged antibiotic treatment in ileocecal Crohn’s disease: single center non-randomized prospective study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Vardanyan, A.(1);Ovsyannikova, V.(2);Peda , E.(3);Nanaeva, B.(3);Achkasov, S.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P581: Transmural remission improves clinical outcomes up to 5 years in patients with Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Pedro, J.(1);Botto, I.(1);Fernandes, S.(1);Lemos, J.(2);Neves, J.(3);Campelo, P.(3);Carvalho, D.(4);Bernardo, S.(1);Gonçalves, A.R.(1);Valente, A.(1);Moura Santos, P.(1);Rosa, I.(2);Tavares de Sousa, H.(3);Ramos, J.(4);Venâncio, J.(5);Leitão, J.(6);Claro, I.(2);Correia, L.(1);Tato Marinho, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P582 Adalimumab therapeutic drug monitoring: Does time of testing matter?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Shields1, J.P. Seenan1, A. Dunlop2, P. Galloway2, J. Macdonald1

Created: Thursday, 30 January 2020, 10:12 AM
P582: Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Yanofsky, R.(1);Abduallah, Y.(1);Golovics, P.(2);Lakatos, P.L.(2);Bitton, A.(2);Wild, G.(2);Afif, W.(2);Bessissow, T.(2);
Created: Friday, 11 February 2022, 3:56 PM
P582: Effectiveness and nephrotoxicity of long-term tacrolimus administration in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Haga*1, T. Shibuya1, K. Okahara1, M. Kamei1, M. Takahashi1, O. Nomura1, D. Ishikawa1, N. Sakamoto1, T. Osada2, A. Nagahara1

Created: Friday, 22 February 2019, 9:41 AM
P582: Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Sands, B.E.(2);Dubinsky, M.C.(3);Feagan, B.G.(4);Panaccione, R.(5);Jairath, V.(6);Yarur, A.(7);Chiorean, M.(8);Panés, J.(9);Goetsch, M.(10);Rabbat, C.J.(11);Shah, P.(12);Wu, J.(13);Ghosh, S.(14);
Created: Friday, 14 July 2023, 11:05 AM
P582: Insights on the sphingolipid profile in patients with short bowel syndrome and consecutive intestinal failure
Year: 2021
Source: ECCO'21 Virtual
Authors: Kubesch, A.(1);Knauer, F.(1);Thomas, D.(2);Jakobi, K.(3);Filmann, N.(4);Zeuzem, S.(1);Pfeilschifter, J.(3);Grammatikos, G.(1);Blumenstein, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P582: The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Han S., Kim S., Kim J., Kwon D.-H., Choi J.-S., Yoon S.-R., Yun S.-H., Kim D.-S., Bae J.-H., Choi H.-J., Sung H.-Y., Yoon S.-W.

Created: Wednesday, 20 February 2019, 10:36 AM
P582: Vedolizumab: Effects on liver function in an IBD and IBD/PSC cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Doherty*, M. Buckley, G. Cullen, G. Horgan, H. Mulcahy, G. Doherty, J. Sheridan

Created: Thursday, 21 February 2019, 9:14 AM
P583 The prevalence of side effects to immunomodulators and biologics in patients with Crohn’s disease intestinal failure compared with Crohn’s disease without intestinal failure
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Bouri1, J. Geldof1, J. Willsmore2, S. Donnelly2, S. Gabe2, A. Hart1

Created: Thursday, 30 January 2020, 10:12 AM
P583: Efficacy of vedolizumab (VDZ) by disease extension in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Michetti1*, F. Braegger2, C. Kempf2, M. Allez3

Created: Thursday, 21 February 2019, 9:14 AM
P583: Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on adalimumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Yerlioglu*1, L. Cococcioni1, A. ElZein1, S. Chadokufa1, R. Buckingham1, S. Sider1, N. Shah1, A. Ocholi1, O. Borrelli1, F. Kiparissi1

Created: Friday, 22 February 2019, 9:41 AM
P583: Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Mocci, G.(1);Cuomo, A.(2);Allegretta, L.(3);Aragona, G.(4);Colucci, R.(5);Della Valle, N.(6);Ferronato, A.(7);Forti, G.(8);Gaiani, F.(9);Graziani, M.G.(10);Lorenzetti, R.(11);Luzza, F.(12);Penna, A.(13);Pica, R.(14);Piergallini, S.(15);Rodinò, S.(16);Scarcelli, A.(17);Zampaletta, C.(18);Cicerone, C.(19);Cocco, A.(20);De Angelis, G.(9);Donnarumma, L.(2);Pranzo, G.(21);Franceschi, M.(7);Gallina, S.(18);Grasso, G.(3);Larussa, T.(12);Luppino, I.(22);Faggiani, R.(23);Fanigliulo, L.(24);Pagnini, C.(10);Perazzo, P.(4);Sacco, R.(6);Sebkova, L.(16);Serio, M.E.(25);De Monti, A.(26);Picchio, M.(27);Elisei, W.(28);Maconi, G.(26);Tursi, A.(29);
Created: Wednesday, 2 June 2021, 4:12 PM
P583: Tofacitinib for acute severe ulcerative colitis: a systematic review
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ovesen, P.D.(1)*;Brynskov, J.(1);Seidelin, J.B.(1);Steenholt, C.(1);
Created: Friday, 14 July 2023, 11:05 AM
P583: Trends in endoscopy management after surgery in a national cohort of Spanish Crohn's disease patients. Results from PRACTICROHN study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Barreiro-de Acosta M.*1, Iborra M.2, García V.3, Gutiérrez A.4, Garcia S.5, Domènech E.6, Martín Arranz M.D.7, Cea-Calvo L.8, Romero C.8, Juliá B.8

Created: Wednesday, 20 February 2019, 10:36 AM
P583: Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicenter cohort study
Year: 2022
Source: ECCO'22
Authors: Avni Biron, I.(1);Mishael, T.(2);Zittan, E.(3);Livne, M.(4);Zinger, A.(5);Tzadok, R.(6); Goldenberg, R.(7);kopylov, U.(4);Ron, Y.(6);Hadar, E.(8);Helman, S.(2);Ollech, J.(1);Farkash, R.(7);Pauker, M.(1);Yanai, H.(1);Dotan, I.(1);Bar-Gil Shitrit , A.(7);
Created: Friday, 11 February 2022, 3:56 PM
P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Hernandez Camba1, L. Arranz1, I. Vera2, D. Carpio3, M. Calafat Sard4, A. Lucendo5, C. Taxonera6, S. Marín7, M.J. Garcia8, G. Suris Marín9, E. Sánchez Rodríguez10, A.Y. Carbajo11, M.L. De Castro12, M. Iborra13, A. Martin-Cardona14, I. Rodríguez Lago15, D. Busquets16, F. Bertoletti17, M. Sierra Ausín18, C. Tardillo1, J. Huguet Malaves19, L. Bujanda20, A. Castaño21, O. Merino22, E. Domènch23, L. Ramos24, ENEIDA Project of GETECCU

Created: Thursday, 30 January 2020, 10:12 AM
P584: A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rasmussen M.*1, Brynskov J.1, Ainsworth M.A.1, Buhl S.1, Bendtzen K.2, Steenholdt C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P584: Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Park1, Y. Kang1, H. Koh1, S. Kim*1

Created: Friday, 22 February 2019, 9:41 AM